


The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number RIGL-004CON4.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: December 6, 2002

By:   
Pamela J. Sherwood  
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP  
200 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231



RECEIVED  
DEC 31 2002  
TECH CENTER 1600/2900

Atty Dkt. No.: RIGL-004CON4  
USSN: 09/919,635

MARKED UP VERSION OF THE CLAIMS

Cancel claims 23-25 and 46-50.

28. (amended) A method according to [claim 23 or] claim 26 further comprising the step:

d) isolating a target molecule using

i) said candidate nucleic acid; or

ii) the expression product of said candidate nucleic acid.

29. (amended) A method according to [claim 23 or] claim 26 wherein said nucleic acids further comprise a presentation sequence capable of presenting said expression product in a conformationally restricted form.

30. (amended) A method according to [claim 23 or] claim 26 wherein said introducing is with retroviral vectors.

31. (amended) A method according to [claim 23 or] claim 26 wherein said cells are mammalian cells.

32. (amended) A method according to [claim 23 or] claim 26 wherein said library comprises at least  $10^4$  different nucleic acids.

33. (amended) A method according to [claim 23 or] claim 26 wherein said library comprises at least  $10^5$  different nucleic acids.

34. (amended) A method according to [claim 23 or] claim 26 wherein said library comprises at least  $10^6$  different nucleic acids.

35. (amended) A method according to [claim 23 or] claim 26 wherein said library comprises at least  $10^7$  different nucleic acids.

36. (amended) A method according to [claim 23 or] claim 26 wherein said library comprises at least  $10^8$  different nucleic acids.

37. (amended) A method according to [claim 23 or] claim 26 wherein each of said candidate nucleic acids is linked to nucleic acid encoding at least one fusion partner.